Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer, Ageing and Somatic Mutation Programme, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.
Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.
The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities such as angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. Herein, to improve the current molecular classification between AITL and PTCL-NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their molecular configuration and integrated them with genomic data of recurrently mutated genes (RHOA , TET2, IDH2 , and DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included in the series. Our analysis unraveled that the mutational status of RHOA , TET2, and DNMT3A poorly correlated, individually, with peculiar transcriptional fingerprints. Conversely, in IDH2 samples a strong transcriptional signature was identified that could act as a surrogate for mutational status. The integrated analysis of clinical, mutational, and molecular data led to a simplified 19-gene signature that retains high accuracy in differentiating the main nodal PTCL entities. The expression levels of those genes were confirmed in an independent cohort profiled by RNA-sequencing.
外周 T 细胞淋巴瘤 (PTCL) 的组织学诊断可能具有挑战性,特别是在密切相关的实体如血管免疫母细胞性 T 细胞淋巴瘤 (AITL)、未特指的 PTCL (PTCL-NOS) 和 ALK 阴性间变性大细胞淋巴瘤 (ALCL)的情况下。尽管基因表达谱和下一代测序已被证明可定义与不同实体频繁相关的特定特征,但基于基因组的分层尚未导致明确的诊断标准和/或进入常规临床实践。在此,为了改善 AITL 和 PTCL-NOS 之间的当前分子分类,我们分析了根据分子构象分层的 503 例 PTCL 的转录谱,并将其与包含在该系列中的 53 例 (39 例 AITL 和 14 例 PTCL-NOS) 中反复突变基因 (RHOA、TET2、IDH2 和 DNMT3A) 的基因组数据进行了整合。我们的分析表明,RHOA、TET2 和 DNMT3A 的突变状态单独与特定的转录指纹相关性差。相反,在 IDH2 样本中鉴定出一个强大的转录特征,可作为突变状态的替代物。临床、突变和分子数据的综合分析导致了一个简化的 19 基因特征,该特征在区分主要结外 PTCL 实体方面具有高准确性。这些基因的表达水平在通过 RNA-seq 进行的独立队列中得到了验证。